Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Epidemiology and treatment of multiple sclerosis in elderly populations.

Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B.

Nat Rev Neurol. 2019 Jun;15(6):329-342. doi: 10.1038/s41582-019-0183-3. Review.

PMID:
31000816
2.

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Vaughn CB, Kavak KS, Dwyer MG, Bushra A, Nadeem M, Cookfair DL, Ramanathan M, Benedict RH, Zivadinov R, Goodman A, Krupp L, Motl RW, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619. [Epub ahead of print]

PMID:
30507270
3.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
4.

Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis.

Younus Z, Vaughn CB, Sanai SA, Kavak KS, Gupta S, Nadeem M, Teter BE, Noyes K, Zivadinov R, Edwards K, Coyle PK, Goodman A, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Int J MS Care. 2017 Nov-Dec;19(6):297-302. doi: 10.7224/1537-2073.2016-058.

5.

Ketogenic diet: Predictors of seizure control.

Agarwal N, Arkilo D, Farooq O, Gillogly C, Kavak KS, Weinstock A.

SAGE Open Med. 2017 Jun 6;5:2050312117712887. doi: 10.1177/2050312117712887. eCollection 2017.

6.

Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.

Bourne T, Waltz M, Casper TC, Kavak K, Aaen G, Belman A, Benson L, Candee M, Chitnis T, Graves J, Greenberg B, Gorman M, Harris Y, Krupp L, Lotze T, Mar S, Ness J, Olsen C, Roalstad S, Rodriguez M, Rose J, Rubin J, Schreiner T, Tillema JM, Kahn I, Waldman A, Barcellos L, Waubant E, Weinstock-Guttman B; US Network of Pediatric MS Centers.

J Neurol Sci. 2017 Apr 15;375:371-375. doi: 10.1016/j.jns.2017.02.041. Epub 2017 Feb 20.

7.

Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis.

Salins S, Teter B, Kavak K, Wolfe GI, Silvestri NJ.

J Clin Neuromuscul Dis. 2016 Dec;18(2):61-66.

PMID:
27861217
8.

Time interval providing highest yield for initial EEG in patients with new onset seizures.

Sofat P, Teter B, Kavak KS, Gupta R, Li P.

Epilepsy Res. 2016 Nov;127:229-232. doi: 10.1016/j.eplepsyres.2016.08.024. Epub 2016 Aug 31.

PMID:
27639127
9.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016 Sep 9.

PMID:
27772741
10.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937-43. doi: 10.1136/jnnp-2015-312221. Epub 2016 Jan 18.

PMID:
26780938
11.

Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.

Chouhfeh L, Kavak KS, Teter BE, Weinstock-Guttman B.

Mult Scler Relat Disord. 2015 May;4(3):228-33. doi: 10.1016/j.msard.2015.02.004. Epub 2015 Feb 27.

PMID:
26008939
12.

Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.

Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

Mult Scler. 2015 Jun;21(7):858-65. doi: 10.1177/1352458514555787. Epub 2014 Nov 12.

PMID:
25392327
13.

Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.

Teter B, Agashivala N, Kavak K, Chouhfeh L, Hashmonay R, Weinstock-Guttman B.

Mult Scler. 2014 Jun;20(7):830-6. doi: 10.1177/1352458513513058. Epub 2013 Nov 25.

PMID:
24277325
14.

Osseous and Nonosseous Bone Scan Findings in Liver Transplant Candidates with end-stage Chronic Liver Disease.

Erhamamcı S, Aktaş A, Bahçeci T, Kavak K.

Mol Imaging Radionucl Ther. 2013 Aug;22(2):23-31. doi: 10.4274/Mirt.29292. Epub 2013 Aug 1.

15.

Unusual urethral F18-FDG accumulation on PET/CT.

Kavak K, Aydin M.

Clin Nucl Med. 2009 Jan;34(1):57-8. doi: 10.1097/RLU.0b013e31818f4482. No abstract available.

PMID:
19092392
16.

The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure.

Aktaş A, Kavak K, Kocabaş B, Aras M, Tütüncü NB, Gençoğlu A.

Nucl Med Commun. 2008 Nov;29(11):943-8. doi: 10.1097/MNM.0b013e32831089e0.

PMID:
18836371

Supplemental Content

Support Center